Rethinking HER2 Status: Practical Testing Considerations for HER2-Low and -Ultralow Advanced Breast Cancer

Please visit answersincme.com/DZU860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Michelle Jacobson, MD, MHSc, FRCSC, MSCP; Nadia Harbeck, MD, PhD; and Renate Haidinger. In this activity, experts in breast cancer and menopause discuss the burden of vasomotor symptoms (VMS) due to breast cancer treatment and the emerging role of neurokinin (NK) receptor antagonists in alleviating these symptoms in practice, with insights from a patient advocate. Upon completion of this activity, participants should be better able to: Recognize VMS as a consequence of breast cancer treatment; Outline the clinical rationale for novel therapeutic approaches to manage VMS associated with breast cancer treatment; Evaluate the efficacy and safety of NK receptor antagonists for breast cancer treatment–associated VMS; and Implement patient-centered clinical approaches to elevate the quality of life of patients experiencing breast cancer–associated VMS.

Please visit answersincme.com/860/MED-CMB-03166-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Samuel S. Gidding, MD; Pamela B. Morris, MD, FACC and Allison Jamison. In this activity, experts in homozygous familial hypercholesterolemia (HoFH) discuss screening, diagnosis, and treatment strategies to support effective management of this rare inherited lipid disorder. Upon completion of this activity, participants should be better able to: Identify strategies to screen and diagnose HoFH; Review the treatment landscape of HoFH, including the role of LDLR-independent therapies; and Outline patient-centered practical strategies to enhance the management of children and adults with HoFH.

Please visit answersincme.com/860/240201356-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Sue D. Pedersen, MD, FRCPC, DABOM; Leon Waye, MD; and Basel Bari, MD, MCFP. In this activity, experts in obesity discuss treatment management with a focus on the role of incretin-based therapies. Upon completion of this activity, participants should be better able to: Explain the rationale for managing obesity as a chronic, treatable disease; Discuss the latest evidence for incretin-based therapies in the management of obesity, including clinical outcomes and safety profiles; and Identify patients who might benefit from incretin-based therapies as part of a comprehensive treatment plan for obesity.

Please visit answersincme.com/CZS860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Giuseppe Curigliano, MD, PhD. In this activity, an expert in oncology discusses the differentiation of patients with HER2-low/ultralow/negative advanced breast cancer and treatment with antibody-drug conjugates. Upon completion of this activity, participants should be better able to: Differentiate HER2-low, -ultralow, and -negative advanced breast cancer; Identify patients with HER2-low and -ultralow advanced breast cancer who would benefit from treatment with antibody-drug conjugates; and Apply evidence-based strategies to connect testing to treatment in patients with HER2-low or -ultralow advanced breast cancer.

Please visit answersincme.com/860/160204316-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Tina Bhutani, MD, MAS, FAAD; and Robin K. Dore, MD. In this activity, experts in dermatology and rheumatology discuss the use of TYK2 inhibitors in the treatment of patients with psoriatic disease, including PsA. Upon completion of this activity, participants should be better able to: Discuss the rationale for using novel TYK2 inhibitors in the treatment of patients with psoriatic disease, including PsA; Review the latest evidence on the use of novel TYK2 inhibitors in patients with psoriatic disease, including PsA; and Outline multidisciplinary strategies for the optimal integration of novel TYK2 inhibitors into treatment plans for patients with psoriatic disease, including PsA.

Please visit answersincme.com/YMM860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Nitish Mehta, MD; and Sarwar Zahid, MD. In this activity, experts in diabetic retinopathy discuss long-acting anti-VEGF agents and strategies to improve outcomes for patients with diabetic macular edema (DME). Upon completion of this activity, participants should be better able to: Recognize factors that contribute to patients' treatment burden with intravitreal anti-VEGF therapies for diabetic macular edema (DME); Assess the clinical profiles of long-acting intravitreal anti-VEGF agents for DME; and Recommend individualized strategies to enhance long-term treatment outcomes for patients with DME.

Please visit answersincme.com/RCG860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Raymond Osarogiagbon, MD, MBBS, FACP, FASCO; and Michael Gieske, MD. In this activity, experts in lung cancer discuss practical strategies for lung cancer screening. Upon completion of this activity, participants should be better able to: Recognize barriers to achieving lung cancer screening for eligible patients; Identify patients at high risk of lung cancer who are eligible for screening; and Outline practical, patient-centered strategies to appropriately integrate lung cancer screening into routine practice.

Please visit answersincme.com/860/29264-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Aditya Bardia, MD and Tiffany A. Traina, MD, FASCO. In this activity, experts in breast cancer share evidence-based insights on integrating current and emerging TROP2-directed antibody-drug conjugates (ADCs) into real-world triple-negative breast cancer (TNBC) care. Upon completion of this activity, participants should be better able to: Identify the role of TROP2-directed antibody-drug conjugates (ADCs) in metastatic triple-negative breast cancer (TNBC) treatment; Compare the latest clinical data on available and emerging TROP2-targeting ADCs for the first-line treatment of patients with TNBC; and Discuss evidence-based strategies to optimize the selection of appropriate patients for first-line treatment with TROP2-targeting ADCs.

Please visit answersincme.com/860/99519635-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Guillermo Garcia-Manero, MD and John Mascarenhas, MD. In this activity, experts in Myelodysplastic Syndromes discuss the latest data for the treatment of anemia in patients with MDS and myelofibrosis. Upon completion of this activity, participants should be better able to: Discuss the latest data for the treatment of anemia in patients with myelodysplastic syndromes (MDS) and myelofibrosis (MF); and Translate the latest data into real-world treatment plans for the treatment of anemia.

Please visit answersincme.com/KEC860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Jonathan E. Rosenberg, MD and Dayna A. Leis, NP. In this activity, experts in genitourinary oncology management discuss evidence-based first-line approaches for advanced urothelial carcinoma (UC) and share practical strategies to recognize and manage adverse events (AEs) through coordinated, multidisciplinary care. Upon completion of this activity, participants should be better able to: Review guideline-recommended first-line systemic treatments for patients with advanced UC; Identify AEs among patients receiving preferred first-line systemic treatment for advanced UC; and Outline multidisciplinary strategies to optimize care for patients receiving preferred first-line systemic treatment for advanced UC.